RA Capital Management
Latest statistics and disclosures from Ra Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ASND, LEGN, PCVX, IMGN, ETNB, and represent 43.60% of Ra Capital Management's stock portfolio.
- Added to shares of these 10 stocks: IMGN (+$174M), CBAY (+$104M), EVH (+$75M), TSHA (+$58M), Apogee Therapeutics (+$42M), SLNO (+$37M), GERN (+$31M), MDGL (+$30M), ANTX (+$29M), SPRY (+$24M).
- Started 14 new stock positions in THRD, TSHA, SLNO, EVH, BCYC, CMRX, CMPS, NKTR, MDGL, UNCY. Apogee Therapeutics, MGNX, URGN, CBAY.
- Reduced shares in these 5 stocks: Dice Therapeutics (-$365M), ASND (-$47M), CTKB (-$30M), DSGN (-$19M), CVAC (-$11M).
- Sold out of its positions in Dice Therapeutics, DSGN.
- Ra Capital Management was a net buyer of stock by $263M.
- Ra Capital Management has $5.1B in assets under management (AUM), dropping by -4.09%.
- Central Index Key (CIK): 0001346824
Tip: Access up to 7 years of quarterly data
Positions held by RA Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Ra Capital Management
Ra Capital Management holds 66 positions in its portfolio as reported in the September 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ascendis Pharma A S (ASND) | 19.8 | $1.0B | -4% | 11M | 93.64 |
|
| Legend Biotech 2 Adr Rep Ord (LEGN) | 8.3 | $421M | 6.3M | 67.17 |
|
|
| Vaxcyte Sponsored Ads (PCVX) | 7.9 | $402M | 7.9M | 50.98 |
|
|
| ImmunoGen (IMGN) | 4.2 | $211M | +471% | 13M | 15.87 |
|
| 89bio (ETNB) | 3.5 | $176M | 11M | 15.44 |
|
|
| Biogen Sponsored Adr (BIIB) | 2.7 | $137M | 533k | 257.01 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 2.6 | $130M | 5.7M | 22.93 |
|
|
| Aerovate Therapeutics (AVTE) | 2.2 | $112M | 8.3M | 13.57 |
|
|
| Cymabay Therapeutics (CBAY) | 2.0 | $104M | NEW | 6.9M | 14.91 |
|
| Verona Pharma Plc ads (VRNA) | 2.0 | $103M | 6.3M | 16.30 |
|
|
| Tyra Biosciences (TYRA) | 2.0 | $100M | 7.2M | 13.77 |
|
|
| Wave Life Sciences (WVE) | 1.9 | $99M | 17M | 5.75 |
|
|
| Geron Corporation (GERN) | 1.9 | $98M | +46% | 46M | 2.12 |
|
| Day One Biopharmaceuticals I (DAWN) | 1.9 | $96M | 7.8M | 12.27 |
|
|
| Janux Therapeutics (JANX) | 1.8 | $92M | +5% | 9.2M | 10.08 |
|
| An2 Therapeutics (ANTX) | 1.8 | $89M | +47% | 5.6M | 16.08 |
|
| Inhibrx SH (INBX) | 1.7 | $87M | +22% | 4.7M | 18.35 |
|
| Rxsight (RXST) | 1.7 | $85M | 3.1M | 27.89 |
|
|
| Newamsterdam Pharma Co Nv Ord Shs (NAMS) | 1.6 | $83M | 9.0M | 9.25 |
|
|
| Evolent Health (EVH) | 1.5 | $75M | NEW | 2.7M | 27.23 |
|
| Curevac N V (CVAC) | 1.4 | $72M | -13% | 11M | 6.83 |
|
| Axsome Therapeutics Class A Ord Shs (AXSM) | 1.4 | $70M | 1.0M | 69.89 |
|
|
| Cogent Biosciences (COGT) | 1.2 | $63M | 6.4M | 9.75 |
|
|
| Acumen Pharmaceuticals Common Stock (ABOS) | 1.2 | $62M | +52% | 15M | 4.15 |
|
| Taysha Gene Therapies (TSHA) | 1.1 | $58M | NEW | 19M | 3.16 |
|
| Gh Research Sponsored Adr (GHRS) | 1.1 | $56M | 5.6M | 10.05 |
|
|
| Alpine Immune Sciences (ALPN) | 1.1 | $54M | 4.7M | 11.45 |
|
|
| 4d Molecular Therapeutics In (FDMT) | 1.0 | $53M | +35% | 4.2M | 12.73 |
|
| Fulcrum Therapeutics (FULC) | 1.0 | $52M | 12M | 4.44 |
|
|
| Iteos Therapeutics (ITOS) | 1.0 | $48M | 4.4M | 10.95 |
|
|
| Vor Biopharma (VOR) | 0.9 | $48M | 23M | 2.12 |
|
|
| Icosavax (ICVX) | 0.9 | $46M | 6.0M | 7.75 |
|
|
| Acrivon Therapeutics (ACRV) | 0.9 | $46M | 4.8M | 9.56 |
|
|
| Apogee Therapeutics | 0.8 | $42M | NEW | 2.0M | 21.30 |
|
| Pepgen (PEPG) | 0.8 | $41M | 8.1M | 5.08 |
|
|
| Avidity Biosciences Ord (RNA) | 0.8 | $41M | 6.4M | 6.38 |
|
|
| Cytek Biosciences (CTKB) | 0.7 | $38M | -44% | 6.8M | 5.52 |
|
| Soleno Therapeutics (SLNO) | 0.7 | $37M | NEW | 1.2M | 29.51 |
|
| Silverback Therapeutics (SPRY) | 0.7 | $36M | +214% | 9.5M | 3.78 |
|
| Eliem Therapeutics Ads (ELYM) | 0.7 | $35M | 13M | 2.63 |
|
|
| Miragen Therapeutics (VRDN) | 0.6 | $31M | 2.0M | 15.34 |
|
|
| Pliant Therapeutics (PLRX) | 0.6 | $31M | 1.8M | 17.34 |
|
|
| Mineralys Therapeutics (MLYS) | 0.6 | $30M | 3.2M | 9.51 |
|
|
| Aclaris Therapeutics Sponsored Ads (ACRS) | 0.6 | $30M | 4.4M | 6.85 |
|
|
| Madrigal Pharmaceuticals (MDGL) | 0.6 | $30M | NEW | 205k | 146.04 |
|
| Enliven Therapeutics (ELVN) | 0.6 | $29M | 2.1M | 13.66 |
|
|
| Eyepoint Pharmaceuticals (EYPT) | 0.5 | $27M | 3.4M | 7.99 |
|
|
| Urogen Pharma (URGN) | 0.4 | $21M | NEW | 1.5M | 14.01 |
|
| Tenaya Therapeutics (TNYA) | 0.3 | $17M | +10% | 6.7M | 2.55 |
|
| Bicycle Therapeutics Plc- Sponsored Adr (BCYC) | 0.3 | $16M | NEW | 800k | 20.09 |
|
| Werewolf Therapeutics (HOWL) | 0.3 | $13M | 6.1M | 2.14 |
|
|
| Celcuity (CELC) | 0.3 | $13M | 1.4M | 9.14 |
|
|
| Nektar Therapeutics (NKTR) | 0.2 | $11M | NEW | 19M | 0.60 |
|
| Nkarta (NKTX) | 0.2 | $11M | 7.8M | 1.39 |
|
|
| Black Diamond Therapeutics (BDTX) | 0.2 | $10M | 3.5M | 2.87 |
|
|
| Compass Pathways (CMPS) | 0.2 | $9.5M | NEW | 1.3M | 7.40 |
|
| Solid Biosciences (SLDB) | 0.2 | $8.6M | 3.4M | 2.52 |
|
|
| Igm Biosciences (IGMS) | 0.2 | $7.8M | 938k | 8.35 |
|
|
| Talaris Therapeutics (TALS) | 0.1 | $6.8M | +3% | 2.4M | 2.81 |
|
| Chimerix (CMRX) | 0.1 | $6.2M | NEW | 6.5M | 0.96 |
|
| Third Harmonic Bio (THRD) | 0.1 | $6.1M | NEW | 962k | 6.39 |
|
| Connect Biopharma Hldgs (CNTB) | 0.1 | $5.7M | 7.0M | 0.82 |
|
|
| Unicycive Therapeutics (UNCY) | 0.1 | $3.0M | NEW | 3.5M | 0.86 |
|
| Nanostring Technologies Ordinary Shares (NSTG) | 0.1 | $3.0M | 1.7M | 1.72 |
|
|
| Macrogenics (MGNX) | 0.0 | $1.6M | NEW | 342k | 4.66 |
|
| Newamsterdam Pharma Co Nv-27 Ord Shs (NAMSW) | 0.0 | $633k | 333k | 1.90 |
|
Past Filings by Ra Capital Management
SEC 13F filings are viewable for Ra Capital Management going back to 2010
- Ra Capital Management 2023 Q3 amended filed Nov. 15, 2023
- Ra Capital Management 2023 Q3 filed Nov. 14, 2023
- Ra Capital Management 2023 Q2 filed Aug. 14, 2023
- Ra Capital Management 2023 Q1 filed May 15, 2023
- Ra Capital Management 2022 Q4 filed Feb. 14, 2023
- Ra Capital Management 2022 Q3 filed Nov. 14, 2022
- Ra Capital Management 2022 Q2 filed Aug. 15, 2022
- Ra Capital Management 2022 Q1 filed May 16, 2022
- Ra Capital Management 2021 Q4 filed Feb. 14, 2022
- Ra Capital Management 2021 Q3 filed Nov. 15, 2021
- Ra Capital Management 2021 Q2 filed Aug. 16, 2021
- Ra Capital Management 2021 Q1 filed May 17, 2021
- Ra Capital Management 2020 Q4 filed Feb. 16, 2021
- Ra Capital Management 2020 Q3 filed Nov. 16, 2020
- Ra Capital Management 2020 Q2 filed Aug. 14, 2020
- Ra Capital Management 2020 Q1 filed May 15, 2020